- Home
- ADVM vs ADAG Comparison
ADVM vs ADAG Comparison
Compare ADVM & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADVM
- ADAG
- Stock Information
- Founded
- ADVM 2006
- ADAG 2011
- Country
- ADVM United States
- ADAG China
- Employees
- ADVM N/A
- ADAG N/A
- Industry
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- ADVM Health Care
- ADAG Health Care
- Exchange
- ADVM Nasdaq
- ADAG Nasdaq
- Market Cap
- ADVM 47.4M
- ADAG 91.4M
- IPO Year
- ADVM 2014
- ADAG 2021
- Fundamental
- Price
- ADVM $2.54
- ADAG $1.92
- Analyst Decision
- ADVM Strong Buy
- ADAG Strong Buy
- Analyst Count
- ADVM 5
- ADAG 1
- Target Price
- ADVM $23.80
- ADAG $8.00
- AVG Volume (30 Days)
- ADVM 312.5K
- ADAG 51.2K
- Earning Date
- ADVM 08-11-2025
- ADAG 07-24-2025
- Dividend Yield
- ADVM N/A
- ADAG N/A
- EPS Growth
- ADVM N/A
- ADAG N/A
- EPS
- ADVM N/A
- ADAG N/A
- Revenue
- ADVM $1,000,000.00
- ADAG $103,204.00
- Revenue This Year
- ADVM N/A
- ADAG $6,488.89
- Revenue Next Year
- ADVM $18.82
- ADAG $57.50
- P/E Ratio
- ADVM N/A
- ADAG N/A
- Revenue Growth
- ADVM N/A
- ADAG N/A
- 52 Week Low
- ADVM $1.78
- ADAG $1.33
- 52 Week High
- ADVM $10.14
- ADAG $3.58
- Technical
- Relative Strength Index (RSI)
- ADVM 51.83
- ADAG 56.78
- Support Level
- ADVM $2.19
- ADAG $1.74
- Resistance Level
- ADVM $2.75
- ADAG $1.98
- Average True Range (ATR)
- ADVM 0.22
- ADAG 0.12
- MACD
- ADVM 0.04
- ADAG -0.00
- Stochastic Oscillator
- ADVM 64.06
- ADAG 72.22
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.